Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.41 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL765447 | 1.00 | CA14 (0.44) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL8659048 | 1.00 | CA14 (0.44) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL24072865 | 0.89 | SMN1; SMN2 (0.46) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL1557617 | 0.89 | SMN1; SMN2 (0.46) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL23499675 | 0.84 | SMN1; SMN2 (0.42) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL12764098 | 0.82 | SMN1; SMN2 (0.41) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL23499631 | 0.82 | SMN1; SMN2 (0.41) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL12951364 | 0.80 | SMN1; SMN2 (0.39) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL20751955 | 0.80 | SMN1; SMN2 (0.39) | CA14MMESMN1; SMN2CA12CA7 | |
| SCHEMBL20751878 | 0.80 | SMN1; SMN2 (0.39) | CA14MMESMN1; SMN2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20180066018-A1 | CONFORMATIONALLY STABLE ANALOGS OF THE RESPONSE SELECTIVE C5A AGONIST EP67 | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-03-08 | — | — | US | disclosed |
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150344424-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-12-03 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
| US-8927564-B2 | Synthesis of polycyclic alkaloids | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-20130237524-A1 | SYNTHESIS OF POLYCYCLIC ALKALOIDS | RIGEL PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8420689-B2 | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-04-16 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-7560480-B2 | Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | DAIICHI ASUBIO MEDICAL RESEARCH LABORATORIES LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CA14 4026/4885MME 1933/4885SMN1; SMN2 4707/4885 |
| US-20080146811-A1 | Compounds and Methods For Treatment of Thrombosis | F2, SERPINC1, PLAT | CA14 1098/4885MME 1509/4885SMN1; SMN2 4353/4885 |
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | CA14 1239/4885MME 56/4885SMN1; SMN2 250/4885 |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | CA14 4051/4885MME 3997/4885SMN1; SMN2 4598/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CA14 4026/4885MME 1933/4885SMN1; SMN2 4707/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | CA14 3737/4885MME 2189/4885SMN1; SMN2 311/4885 |
| US-20130237524-A1 | SYNTHESIS OF POLYCYCLIC ALKALOIDS | PNMT, ACHE, PRMT5 | CA14 386/4885MME 2458/4885SMN1; SMN2 1331/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | CA14 4233/4885MME 3367/4885SMN1; SMN2 4482/4885 |
| US-20180066018-A1 | CONFORMATIONALLY STABLE ANALOGS OF THE RESPONSE SELECTIVE C5A AGONIST EP67 | C5AR1, C5AR2, C3AR1 | CA14 4718/4885MME 619/4885SMN1; SMN2 3212/4885 |
| US-20150344424-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, UTS2R, MC2R | CA14 1502/4885MME 498/4885SMN1; SMN2 4672/4885 |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CA14 4026/4885MME 1933/4885SMN1; SMN2 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.